The Effect of COVID-19 Patients' Serum Phosphate Level on Mortality in ICU

Covid19 Clinical Trial

Official title:

Phosphate Levels of COVID-19 Patients and Mortality

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04800770
• Other study ID #: E1-21-1584
• Status: Recruiting
• Start date: March 3, 2021
• Est. completion date: July 31, 2021

Study information

• Verified date: March 2021
• Source: Ankara City Hospital Bilkent
• Contact: betül aytaç, MD
• Phone: +905073578351
• Email: drbguven[@]hotmail.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The investigators aimed to investigate the relationship between phosphate level and mortality using the 4C Mortality Score in COVID-19 patients who were followed up in the intensive care unit.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: July 31, 2021
• Est. primary completion date: June 15, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Participants hospitalized in the intensive care unit diagnosed with COVID-19 will incluse in the study

Exclusion Criteria:

• there is no exclusion criteria

Related Conditions & MeSH terms

• Covid19
• Mortality
• Phosphate Deficiency

Intervention

Diagnostic Test:
• 4C mortality score
4C mortality score and phosphate levels

Locations

Country	Name	City	State
Turkey	Ankara City Hospital	Ankara

Sponsors (1)

Lead Sponsor	Collaborator
Ankara City Hospital Bilkent

Country where clinical trial is conducted

Turkey, 

References & Publications (3)

Murer H, Forster I, Biber J. The sodium phosphate cotransporter family SLC34. Pflugers Arch. 2004 Feb;447(5):763-7. Epub 2003 May 16. Review. — View Citation

Pistolesi V, Zeppilli L, Polistena F, Sacco MI, Pierucci A, Tritapepe L, Regolisti G, Fiaccadori E, Morabito S. Preventing Continuous Renal Replacement Therapy-Induced Hypophosphatemia: An Extended Clinical Experience with a Phosphate-Containing Solution — View Citation

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):106 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	4C mortality score	4C Mortality Scores of the patients will be calculated, according to age, gender, number of comorbidities, respiratory rate, SpO2, GCS, urea, and CRP parameters	6 months
Primary	serum phosphate levels	mg/dl	6 months
Primary	mortality	mortality percentage of patients in 28 days	28 days